ESKETAMINE

USFDA approves Nasal Spray with Treatment-Resistant Depression

Icahn School of Medicine Dean Dennis Charney, MD, Co-Invented a atented Method of Treating Patients with Treatment-Resistant Depression Which Is Part of the Drug Application for Janssen’s Newly Approved SPRAVATO™ (esketamine) CIII Nasal Spray